文献速递白血病造血干细胞移植与细胞治疗

原发性难治性急性髓系白血病异基因造血细胞移植预后的预后因素(2013-2022):日本移植与细胞治疗学会成人急性髓系白血病工作组回顾性研究

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy.
PubMed 文献 · Br J Haematol · 2025-06-16

该回顾性研究基于日本国家登记数据,分析2013至2022年间2600例接受首次异基因造血细胞移植的原发性难治性急性髓系白血病成人患者,3年总生存率和无白血病生存率分别为28.5%和24.4%,并基于五个显著风险因素建立评分系统对预后进行分层。

要点

  • 3年总生存率和无白血病生存率分别为28.5%和24.4%。
  • 不良预后因素包括年龄≥50岁、体能状态≥2、不良细胞遗传学、诊断时髓外病变及移植时外周血原始细胞≥10%。
  • 基于五个风险因素建立的评分系统可有效分层总生存率和无白血病生存率。

核心结论

  • 这项全国性分析表明,异基因造血细胞移植为成人原发性难治性急性髓系白血病患者提供了长期生存的可能。
  • 所提出的风险评分系统可能支持临床决策和患者咨询。

研究设计与样本

  • 回顾性分析纳入2013年至2022年间接受首次异基因造血细胞移植的2600例成人原发性难治性急性髓系白血病患者,数据来自日本国家登记库。

主要发现

  • 3年总生存率和无白血病生存率分别为28.5%和24.4%。
  • 多因素分析确定年龄≥50岁、体能状态≥2、不良细胞遗传学、诊断时髓外病变和移植时外周血原始细胞≥10%为总生存率和无白血病生存率较差的显著风险因素。
  • 3年累积复发率和非复发死亡率分别为49.8%和25.8%。
  • 基于五个显著风险因素开发的评分系统有效将患者分为不同的总生存率和无白血病生存率预后组。

关键数值与推荐

  • 3年总生存率为28.5%,无白血病生存率为24.4%。
  • 3年累积复发率为49.8%,非复发死亡率为25.8%。
  • 显著不良预后因素包括年龄≥50岁、体能状态≥2、不良细胞遗传学、诊断时髓外病变和移植时外周血原始细胞≥10%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary refractory acute myeloid leukaemia (AML) remains a major clinical challenge, with poor outcomes despite salvage chemotherapy. Allogeneic haematopoietic cell transplantation (HCT) continues to be a potentially curative option for these patients. However, recent data on outcomes and prognostic factors specific to primary refractory AML remain limited. We conducted a retrospective analysis of 2600 adult patients with primary refractory AML who underwent their first allogeneic HCT between 2013 and 2022, using data from the Japanese national registry. The 3-year overall survival (OS) and leukaemia-free survival (LFS) rates were 28.5% and 24.4% respectively. The multivariate analysis identified older age (≥50 years), poor performance status (≥2), adverse cytogenetics, extramedullary disease at diagnosis and higher peripheral blood blast count at HCT (≥10%) as significant risk factors for worse OS and LFS. The cumulative incidences of relapse and non-relapse mortality at 3 years were 49.8% and 25.8% respectively. Based on the five significant risk factors, we developed a scoring system that effectively stratified patients into distinct prognostic groups for OS and LFS. This nationwide analysis demonstrated that allogeneic HCT offers the potential for long-term survival in adult patients with primary refractory AML. The proposed risk-scoring system may support clinical decision-making and patient counselling.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Konuma T, Shimomura Y, Mizuno S, et al. Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy. Br J Haematol. 2025. PMID: 40518826. doi:10.1111/bjh.20208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。